These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33742748)

  • 41. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
    Ong T; Ramsey BW
    Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cystic Fibrosis-Associated Liver Disease in Lung Transplant Recipients.
    Mallea J; Bolan C; Cortese C; Harnois D
    Liver Transpl; 2019 Aug; 25(8):1265-1275. PubMed ID: 31102574
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis.
    Sergeev V; Chou FY; Lam GY; Hamilton CM; Wilcox PG; Quon BS
    Ann Am Thorac Soc; 2020 Feb; 17(2):147-154. PubMed ID: 31661636
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A combination therapy for cystic fibrosis.
    Brodsky JL; Frizzell RA
    Cell; 2015 Sep; 163(1):17. PubMed ID: 26406363
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
    Bulloch MN; Hanna C; Giovane R
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.
    Ren CL; Morgan RL; Oermann C; Resnick HE; Brady C; Campbell A; DeNagel R; Guill M; Hoag J; Lipton A; Newton T; Peters S; Willey-Courand DB; Naureckas ET
    Ann Am Thorac Soc; 2018 Mar; 15(3):271-280. PubMed ID: 29342367
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
    Brewington JJ; McPhail GL; Clancy JP
    Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cystic Fibrosis: A Novel Pharmacologic Approach to Cystic Fibrosis Transmembrane Regulator Modulation Therapy.
    Virant-Young D; Thomas J; Woiderski S; Powers M; Carlier J; McCarty J; Kupchick T; Larder A
    J Am Osteopath Assoc; 2015 Sep; 115(9):546-55. PubMed ID: 26322933
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cystic fibrosis liver disease in the new era of cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
    Eldredge JA; Oliver MR; Ooi CY
    Paediatr Respir Rev; 2024 Jun; 50():54-61. PubMed ID: 38281822
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis.
    Jarosz-Griffiths HH; Scambler T; Wong CH; Lara-Reyna S; Holbrook J; Martinon F; Savic S; Whitaker P; Etherington C; Spoletini G; Clifton I; Mehta A; McDermott MF; Peckham D
    Elife; 2020 Mar; 9():. PubMed ID: 32118580
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modulators of CFTR. Updates on clinical development and future directions.
    Bardin E; Pastor A; Semeraro M; Golec A; Hayes K; Chevalier B; Berhal F; Prestat G; Hinzpeter A; Gravier-Pelletier C; Pranke I; Sermet-Gaudelus I
    Eur J Med Chem; 2021 Mar; 213():113195. PubMed ID: 33524685
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 53. How Should the Effects of CFTR Modulator Therapy on Cystic Fibrosis Lung Disease Be Monitored?
    Ben-Meir E; Grasemann H
    Am J Respir Crit Care Med; 2022 Aug; 206(3):240-242. PubMed ID: 35579627
    [No Abstract]   [Full Text] [Related]  

  • 54. Tezacaftor/ivacaftor in people with cystic fibrosis heterozygous for minimal function CFTR mutations.
    Munck A; Kerem E; Ellemunter H; Campbell D; Wang LT; Ahluwalia N; Owen CA; Wainwright C
    J Cyst Fibros; 2020 Nov; 19(6):962-968. PubMed ID: 32546431
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Residual function of cystic fibrosis mutants predicts response to small molecule CFTR modulators.
    Han ST; Rab A; Pellicore MJ; Davis EF; McCague AF; Evans TA; Joynt AT; Lu Z; Cai Z; Raraigh KS; Hong JS; Sheppard DN; Sorscher EJ; Cutting GR
    JCI Insight; 2018 Jul; 3(14):. PubMed ID: 30046002
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
    Jones AM; Barry PJ
    Thorax; 2015 Jul; 70(7):615-6. PubMed ID: 26071414
    [No Abstract]   [Full Text] [Related]  

  • 57. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy.
    Connett GJ
    Drug Des Devel Ther; 2019; 13():2405-2412. PubMed ID: 31409974
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical papers of the year 2018 - Cystic fibrosis.
    Balfour-Lynn IM
    Paediatr Respir Rev; 2020 Feb; 33():58-61. PubMed ID: 31053358
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Chronic β2AR stimulation limits CFTR activation in human airway epithelia.
    Brewington JJ; Backstrom J; Feldman A; Kramer EL; Moncivaiz JD; Ostmann AJ; Zhu X; Lu LJ; Clancy JP
    JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467332
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tezacaftor and ivacaftor for the treatment of cystic fibrosis.
    Paterson SL; Barry PJ; Horsley AR
    Expert Rev Respir Med; 2020 Jan; 14(1):15-30. PubMed ID: 31626570
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.